Growing Number of Respiratory Disease Further Propels The Asthma and COPD Drugs Market

Increasing prevalence of  respiratory diseases such as asthma and COPD across the globe further prples the demand of asthma and COPD drugs. As per Centre for Diseases Control and Prevention, about 1 in 13 people in the US have asthma in the US, equal to 25 million people. About 7.5% of adults and 8.5% of children are affected by it in the country. As per Asthma UK, about 5.4 million people are suffering are suffering from asthma in the UK in 2016. Out of 5.4 million people, asthma is prevalent in 4.3 million adults and 1.1 million in children. National Healthcare Service of the UK is spending about $1 billion each year to treat and caring of people with asthma. As per WHO, India is estimated to have about 15-20 million asthma patients in 2017. It is also on high rise in China, as per Asia Asthma Development Board, there were about 36.7 patients of asthma per 100,000 people. There are more than 30 million people living with Asthma in the China. In Australia, there are about 2.5 million people living with asthma. Therefore the increasing prevalence further provide demand of drugs that further propels the market growth.  

Browse the full report description Global Asthma and COPD Drugs Market Size, Share & Trends Analysis Report by Disease Type(Asthma and COPD), By Application (Cardiology, Orthopedics, General Surgery &Anesthesia, Neurology Urology, Others) and Forecast 2020-2026 at https://www.omrglobal.com/industry-reports/asthma-and-copd-drugs-market

Increasing R&D further boost the Asthma and COPD drugs Market 

Researchers are continuously looking for new ways to treat Asthma and COPD and research in various areas such as early detection, new drug therapies and new surgical techniques. Various studies and trails have the method of lung accumulating the damage and way to treat the damage before it respiratory diseases become COPD. Companies such as Vertex Pharmaceuticals, Merck, GlaxoSmithKline, Novartis, AstraZeneca are continuously working toward the research and development. In period of 2015-18, various drugs of these companies have been cleared by FDA for treating respiratory diseases. For instance in April, 2016 AstraZeneca got an FDA approval for Bevespi Aerosphere which have application in treatment of COPD. Before this, Teva Pharmaceuticals got an FDA approval for Cinqair (reslizumab) in March, 2016 which can be used to treat severe asthma. 

Substantial opportunities in emerging markets

A significant growth in the healthcare facilities related to respiratory diseases has been observed in the emerging economies such as China, India and Brazil. Various factors such as increasing air pollution, increasing disposable income & expenditure on healthcare are attracting market players to serve their healthcare organizations. Specifically, Asia-Pacific region is considered to be the most emerging market due to significant growth of healthcare system in Asia-Pacific countries such as India, China, and South Korea. Asia pacific region is forecast to witness immense growth and development in healthcare sector due to significant investment by government and major market players, favourable government policies, high patient base. Asia-Pacific region covers more than 60% of global population, have high prevalence of respiratory diseases such as asthma and COPD therefore provide significant opportunity to the market growth.

Global Asthma and COPD Drugs Market Segmentation

By Disease Type

• Asthma 
• COPD

By Drug class

• Anti-inflammatory Drugs
• Combination Drugs
• Monoclonal Antibodies
• Bronchodilators

Global Asthma and COPD Drugs Market – Segment by Region